Interest of bayesian forecasting of vancomycin dosing regimens in a neonatal intensive care unit;Intérêt de l'individualisation des posologies de vancomycine par une méthode bayésienne dans un service de reanimation néonatale

Journal de Pharmacie Clinique

Volumn 22, Issue 2, 2003, Pages 95-100

  Janoly Dumenil, A ^a   Bleyzac, N ^a   Richard, I ^a   Bourgeois, J ^a   Constant, H ^a   Putet, G ^a   Maire, P ^c   Aulagner, G ^a,b  

^a HÔPITAL DEBROUSSE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c NONE

Author keywords

Adaptive Bayesian control; Neonate; Vancomycin

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BAYES THEOREM; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN INTENSIVE CARE; PHARMACY; RETROSPECTIVE STUDY;

EID: 0042168886     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gabriel MH, Kildoo CW, Gennrich JL, Modanlou HD, Collins SR. Prospective evaluation of a vancomycin dosage guideline for neonates. Clin Pharm 1991; 10: 129-32.
2. Borderon C, Laugier J, Chamboux C, Saliba E, Mathieu A. Perfusion continue de vancomycine en période néonatale. Pathol Biol 1994; 42: 525-9.
3. e ed. Collection Option Bio. Paris: Elsevier, 1994: 479-518.
4. Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Rose JC. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. BrJ Clin Pharmacol 1998; 46: 163-7.
5. USC*Pack PC software. Laboratory of applied pharmacokinetics. Collection clinical research programs. Los Angeles, University of Southern California, School of Medicine, version 10.7, 1995.
6. Jelliffe R, Schumitzky A, Van Guilder M. Individualizing drug dosage regimens. Roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380-93.
7. Rodvold KA, Everett JA, Pryka RD, Kraus DM. Pharmacokinetics and administration regimens of vancomycine in neonates, infants and children. Clin Pharmacokinet 1997; 33: 32-51.
8. De Hoog M, Shoemaker RC, Mouton JW, Van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 2000; 67: 360-7.
9. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001; 41: 927-34.
10. Silva R, Reis E, Bispo MA, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol 1998; 50: 1255-60.
11. Chauvet C, Rochegude S, Bleyzac N, Maire P, Putet G, Aulagner G. Bayesian monitoring of vancomycin concentrations in new borns: choice of the optimal elimination covariate. Meeting of the population approach group in Europe. Saintes, 1999.
12. St Geme III JW, Harris MC. Coagulase negative staphylococcal infection in the neonate. Clin Perinatol 1991; 18: 281-302.
13. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696-700.
14. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
15. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-50.
16. Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993; 27: 490-6.
17. Murphy JE, Slack MK, Campbell S. National survey of hospital-based pharmacokinetic services. Am J Health-Syst Pharm 1996; 53: 2840-7.